Company news

CelLBxHealth plc news in 2024

CelLBxHealth plc's news releases, calls and decks from 2024, newest first.

View company

HER2 presentation at SABCS

December 13, 2024

Research on HER2 assay kit showcased at AACR

November 15, 2024

ANGLE presents two posters at EACR

November 13, 2024

Parsortix enriched CTC & ctDNA in NSCLC patients

November 11, 2024

Publication demonstrates CTC profiling potential

October 17, 2024

100th publication supporting Parsortix system use

September 26, 2024

Exclusive agreement for DNA NGS panel

September 23, 2024

Agreement with Recursion Pharmaceuticals

September 19, 2024

Notice of Interim Results and Webcast

September 17, 2024

Data supporting FDA approval published in Journal

August 22, 2024

Independent Parsortix study

August 1, 2024

Standard form for notification of major holdings

July 18, 2024

Result of 2024 Annual General Meeting

July 11, 2024

Result of open offer

June 21, 2024

Posting of 2023 Annual Report & Notice of the AGM

June 18, 2024

Parsortix and assays being showcased at EACR 2024

June 11, 2024

Publication of Circular

June 6, 2024

Results of placing and subscription

June 5, 2024

Study of ovarian cancer CTCs using Parsortix

May 16, 2024

New commercial agreement with large pharma

May 3, 2024

New commercial agreement with AstraZeneca

April 24, 2024

US and EU patents for innovative CellKeep™ slide

April 22, 2024

Parsortix HER2 assay showcased at AACR 2024

April 8, 2024

Parsortix at European breast cancer conference

March 22, 2024

Potential utility in precision oncology

January 22, 2024

Breakthrough clinical results

January 4, 2024

Contract announcement with Eisai Inc.

January 2, 2024

Decks in 2024